DrugPatentWatch Database Preview
DOPTELET Drug Profile
When do Doptelet patents expire, and when can generic versions of Doptelet launch?
Doptelet is a drug marketed by Akarx Inc and is included in one NDA. There are three patents protecting this drug.
This drug has eighteen patent family members in eleven countries.
The generic ingredient in DOPTELET is avatrombopag maleate. One supplier is listed for this compound. Additional details are available on the avatrombopag maleate profile page.
Summary for DOPTELET
| International Patents: | 18 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 25 |
| Patent Applications: | 29 |
| Drug Prices: | Drug price information for DOPTELET |
| DailyMed Link: | DOPTELET at DailyMed |
Generic Entry Opportunity Date for DOPTELET
Generic Entry Date for DOPTELET*:
Constraining patent/regulatory exclusivity:
TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for DOPTELET
| 1-(3-chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid |
| 1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-4-piperidinecarboxylic acid |
| 1-[3-Chloro-5-[[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazino)-2-thiazolyl]carbamoyl]-2-pyridyl]piperidine-4-carboxylic acid |
| 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid |
| 3H8GSZ4SQL |
| 4-Piperidinecarboxylic acid, 1-(3-chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)- |
| 570406-98-3 |
| A14087 |
| AKR 501 |
| AKR-501 |
| AKR-501;E5501;AS1670542 |
| AS 1670542 |
| AVATROMBOPAG |
| Avatrombopag (USAN/INN) |
| Avatrombopag [USAN:INN] |
| BCP28031 |
| CHEMBL2103883 |
| CS-3397 |
| D10306 |
| DB11995 |
| DTXSID30205667 |
| E 5501 |
| E5501 |
| FT-0728753 |
| GTPL9953 |
| HY-13463 |
| SB16846 |
| SCHEMBL289354 |
| UNII-3H8GSZ4SQL |
| YM 477 |
| YM477 |
| ZINC72190218 |
US Patents and Regulatory Information for DOPTELET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DOPTELET
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2314586 | Start Trial |
| Denmark | 1466912 | Start Trial |
| South Korea | 20040078122 | Start Trial |
| World Intellectual Property Organization (WIPO) | 03062233 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
